Stevanato Group S.p.A. (STVN) Stock Price & How to Invest
Last updated November 2026
Short answer
STVN is Stevanato Group, the Italian family-controlled maker of the glass vials, syringes, cartridges and pen injectors that pharmaceutical companies fill with injectable medicines, trading as ordinary shares on the NYSE rather than as an OTC receipt. Shares closed at ~$15.70 on November 20, 2026 (down ~24% year to date and ~26% over one year) for a market value of ~$4.3 billion against ~EUR 1.25 billion of trailing revenue, after the third-quarter report flagged slower GLP-1 volumes from one customer in 2027.
STVN stock price
As of 2026-11-20, Stevanato Group S.p.A. (STVN) last closed at $15.65, down 30.1% over the past year. Over the past 52 weeks it has traded between $13.21 and $23.43.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Stevanato Group S.p.A.'s investor relations page. Walnut is informational, not investment advice.
STVN key stats
At $15.65 on November 20, 2026, Stevanato Group S.p.A. (STVN) has a market cap of $4.3B, a P/E of 26.5 on trailing earnings (21.6 on forward earnings) and a dividend yield of 0.38%.
- Market cap
- $4.3B
- P/E (trailing)
- 26.5
- P/E (forward)
- 21.6
- EPS (trailing 12 months)
- $0.59
- Price to book
- 2.4
- Dividend yield
- 0.38%
- Beta
- 0.80
Market cap, P/E and yield are measured at the $15.65 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with Stevanato Group S.p.A. (STVN)?
The last two weeks for Stevanato Group S.p.A., as of November 22, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- STVN closed at $15.65 on November 20, 2026, down 0.9% over the past five trading days (from $15.80).
- On November 12, 2026, Stevanato Group S.p.A. filed a current report (6-K) with the SEC. Read the 6-K on sec.gov
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
What does Stevanato Group S.p.A. (STVN) do?
Stevanato Group has been making pharmaceutical glass in Piombino Dese, near Padua in northern Italy, since 1949, and sells its containers under the Ompi brand. The business runs in two segments. Biopharmaceutical and Diagnostic Solutions covers vials, syringes, cartridges, EZ-fill ready-to-use containers and the Alina pen injector platform, and produced ~EUR 294 million of the ~EUR 326.1 million total in the third quarter of 2026. Engineering builds the assembly, visual inspection and glass converting machinery that drug makers and other packaging firms use on their own lines, and contributed the remaining ~EUR 32 million. The company listed ordinary shares on the New York Stock Exchange in July 2021, but it remains an Italian issuer that reports in euros and files as a foreign private issuer, and the founding family retains roughly four fifths of the shares through Stevanato Holding S.r.l., with Italian loyalty-share rules adding extra votes on top of that.
The investment picture turns on mix. Ordinary bulk glass is a commodity with thin margins and a customer base that periodically works down inventory, which is exactly what caused the 2024 destocking shock. What Stevanato calls high-value solutions, meaning sterilized ready-to-use containers and integrated delivery devices, carries far better economics and reached ~46% of third-quarter revenue at ~EUR 149.4 million, though it grew only ~1% year over year as GLP-1 volumes fell, while other containment and delivery solutions grew ~22% and the total grew ~8%. Third-quarter adjusted EBITDA rose ~14% to ~EUR 88.8 million, a ~27.2% margin and up ~150 basis points, and adjusted EPS was ~EUR 0.16. Against that, the company is spending heavily to build the capacity the shift requires, at Fishers in Indiana and Latina in Italy, with full-year capital expenditure guided to ~EUR 230 million to ~EUR 240 million gross. Third-quarter free cash flow turned positive at ~EUR 21.7 million and net debt eased to ~EUR 353.7 million, but buyers of the shares are still funding a multi-year build-out before the returns on it arrive. Stevanato also completed the sale of Balda C. Brewer, a California subsidiary expected to contribute ~EUR 30 million of 2026 revenue, on June 30, and reaffirmed its trimmed full-year guidance with the November results. The stock reaction came from 2027: management said one customer's lower GLP-1 volumes, tied to Nexa syringes, would moderate next year's growth to low single digits, called it a temporary headwind it expects to largely backfill, and reported GLP-1 at ~17% to ~18% of revenue, down from ~22% to ~23% in the second quarter. William Blair downgraded the shares, UBS cut its target to $16 from $23, and plaintiff firms announced investigations into the company's GLP-1 disclosure. As of November 20, 2026 the stock traded at ~$15.70, against a 52-week range of ~$12.05 to ~$24.01.
What's driving Stevanato Group S.p.A. (STVN)?
1. The high-value solutions mix shift
Ready-to-use sterilized containers and integrated delivery systems reached ~46% of third-quarter 2026 revenue at ~EUR 149.4 million, and ~51% within the Biopharmaceutical and Diagnostic Solutions segment. Growth slowed sharply to ~1% year over year in the quarter, from ~16% in the second quarter, because lower GLP-1 volumes sit inside this category. The margin effect of the mix is still visible in the ~27.2% adjusted EBITDA margin, up ~150 basis points, but the pace of the shift now depends on how quickly non-GLP-1 programs fill the gap.
2. Injectable biologics volumes, GLP-1 included
GLP-1 therapies fell to roughly ~17% to ~18% of total revenue in the third quarter, down from ~22% to ~23% on the second-quarter call, while non-GLP-1 biologics revenue rose more than ~30% in the quarter and ~13% year to date. Management continues to frame the wider injectable pipeline as the larger opportunity, having cited more than ~9,000 injectable assets in development with around ~60% of them biologics. Each of those needs a container that will not react with the molecule and, increasingly, a device the patient can use at home, and approval across several European markets for a liraglutide therapy on the Alina pen platform moved Stevanato from selling a component to selling an assembled system. The open question is 2027: one customer's lower GLP-1 volumes tied to Nexa syringes will hold growth to low single digits next year, which management calls temporary, and the 2026 arrival of oral GLP-1 pills adds a second question about how much injectable volume the obesity class will need. Peers are seeing the same pressure, with RBC and UBS both turning cautious on Schott Pharma in November over GLP-1 syringe demand.
3. New capacity in the United States and Italy
The Fishers, Indiana site completed initial performance qualification on its first EZ-fill vial line and expects commercial production for its first device program later in 2026, with full ramp-up guided to the end of 2028. Latina in Italy is running alongside it. Full-year 2026 capital expenditure is guided to ~EUR 230 million to ~EUR 240 million gross, or ~EUR 215 million to ~EUR 225 million net of customer contributions. Pharmaceutical customers under pressure to localize supply chains give a European supplier with US plants an argument it did not have five years ago, though the payoff sits several years out, and slower 2027 volumes stretch the time before the new lines are full.
4. A possible turn in Engineering
Engineering revenue fell ~12% year over year to ~EUR 32 million in the third quarter, after a ~2% decline to ~EUR 35.8 million in the second. Management said the same customer behind the lower GLP-1 forecast is also delaying engineering orders, cut the segment's full-year outlook modestly to ~EUR 124 million to ~EUR 134 million, and said it is still evaluating the segment's strategic path. That makes Engineering a swing factor and possibly a candidate for a structural change, not a reliable driver. The June 2026 sale of the Balda C. Brewer subsidiary already trimmed revenue by ~EUR 30 million this year in exchange for a cleaner margin profile.
What are the risks to Stevanato Group S.p.A. (STVN)?
Customer concentration and destocking have hit this company before and did again in November 2026: after the May 2024 guidance cut on industry-wide vial destocking the shares fell ~22% in a single session, and after the third-quarter 2026 report flagged lower 2027 GLP-1 volumes from one customer the stock dropped ~19% over the following month. Plaintiff firms opened investigations after both episodes, the latest focused on the company's GLP-1 disclosure; those are investigations, not filed litigation, as far as the public record shows. Capital intensity remains the near-term drag, with full-year 2026 capital expenditure guided to ~EUR 230 million to ~EUR 240 million gross, trailing free cash flow of ~negative $65 million on Yahoo's basis and net debt of ~EUR 353.7 million at the end of September. GLP-1 exposure now reads as ~17% to ~18% of revenue, still a single point of failure if pricing, supply or dosing formats change, and the 2026 launch of oral GLP-1 pills turned the dosing-format risk from hypothetical to live. Governance leaves outside holders with limited influence, because family control through Stevanato Holding S.r.l. plus enhanced voting rights means minority shareholders cannot force a change of direction. Finally, the reporting currency is the euro while the quote is in dollars, so a US holder absorbs the exchange rate on top of the operating result, and at roughly ~27 times trailing and ~22 times forward earnings as of November 2026 the price still assumes the mix shift and the new plants deliver once the 2027 slowdown passes.
What is the Stevanato Group S.p.A. (STVN) forecast?
12 analysts publish price targets on STVN, averaging $19.46 as of November 2026, or +24.3% against the $15.65 share price on November 20, 2026. The published targets run from $16.00 to $25.00, a moderate spread, and the ratings split 9 buy, 4 hold, 0 sell. Over the last six months there have been 0 raises and 4 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.
Read the full STVN forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.
Is STVN a buy or a sell?
We give no verdict on Stevanato Group S.p.A.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.
The case for buying. The high-value solutions mix shift. Ready-to-use sterilized containers and integrated delivery systems reached ~46% of third-quarter 2026 revenue at ~EUR 149.4 million, and ~51% within the Biopharmaceutical and Diagnostic Solutions segment. The most optimistic published target, $25.00, assumes this works close to its best case.
The case against. Customer concentration and destocking have hit this company before and did again in November 2026: after the May 2024 guidance cut on industry-wide vial destocking the shares fell ~22% in a single session, and after the third-quarter 2026 report flagged lower 2027 GLP-1 volumes from one customer the stock dropped ~19% over the following month. The most pessimistic target, $16.00, is roughly what STVN is worth if this bites instead.
Read the full bull and bear case on STVN, including what would have to change to break either one. Walnut is not an investment adviser.
Has Stevanato Group S.p.A. (STVN) split its stock?
No. Stevanato Group S.p.A. (STVN) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.
How is Stevanato Group S.p.A. (STVN) valued?
Market cap, P/E and dividend yield at today's price are in the STVN key stats above. The business figures below come from Stevanato Group S.p.A.'s reported results as of November 2026 and change when it next reports.
- Revenue (TTM): ~EUR 1.25 billion, Q3 2026 up ~8% year over year
- Q3 2026 revenue: ~EUR 326.1 million, adjusted diluted EPS ~EUR 0.16 (Yahoo basis 0.18 vs 0.18 est.)
- Margins (TTM): gross ~29%, operating ~18%, net ~11%
- Net income (TTM): ~EUR 140 million
- FY2026 company guidance (reaffirmed): revenue ~EUR 1.26 to ~EUR 1.28 billion, adjusted diluted EPS ~EUR 0.60 to ~EUR 0.62
As of November 2026: Every operating figure above is reported in euros because Stevanato is an Italian issuer, while the share price and market capitalization are quoted in US dollars on the NYSE, so the two sets of numbers move on different currencies and should not be compared directly. The trailing multiple has come down from ~33 times in October to ~27 times as of November 20, 2026, as the shares fell ~19% in a month on the 2027 GLP-1 warning, and consensus now looks for 2027 EPS of ~0.72 on ~EUR 1.3 billion of revenue, about ~6% growth. The analyst mean target was ~$19.46 across 12 analysts, with a Buy consensus despite the William Blair downgrade.
Who competes with Stevanato Group S.p.A. (STVN)?
Primary containment and pharmaceutical glass
West Pharmaceutical Services (NYSE: WST) is the closest US-listed comparable and dominates elastomer stoppers and seals, while Schott Pharma and Gerresheimer, both listed in Frankfurt, compete directly in vials, syringes and cartridges. Schott Pharma drew downgrades from RBC and a cautious call from UBS in November 2026 over the same GLP-1 syringe demand question. Corning, Nipro and SGD Pharma round out the field. Competition here is decided by regulatory qualification more than price, since changing a container means refiling with regulators, which is why incumbents keep programs for years.
Drug delivery devices and pen injectors
Stevanato's Alina platform puts it against Ypsomed, SHL Medical, Phillips-Medisize and Owen Mumford in autoinjectors and pens, alongside Becton Dickinson (NYSE: BDX), which supplies both prefillable syringes and devices at scale. Winning here means being designed into a drug program before approval, so share moves slowly and each win carries a long revenue tail.
Pharmaceutical process and inspection equipment
The Engineering segment sells against Syntegon, Koerber Pharma, IMA Group, Marchesini and Optima for filling lines, assembly systems and visual inspection machinery. Order-driven and lumpy by nature, this business turns on capital budgets at drug makers and contract fillers, and management pointed there when it described sales cycles as elongated and said one large customer was delaying orders.
What stocks are similar to Stevanato Group S.p.A. (STVN)?
Other names that sit close to STVN: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.
How to invest in Stevanato Group S.p.A. (STVN)
There are three common ways to get STVN exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so STVN sits alongside other stocks that express the same thesis.
Walnut takes the portfolio route. Describe a thesis where STVN fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.
The bottom line on Stevanato Group S.p.A. (STVN)
Stevanato is a supplier to the injectable drug industry with a mix shift into premium containment and delivery systems underway, carried at ~27x trailing and ~22x forward earnings as of November 2026 while heavy plant construction keeps trailing free cash flow negative. The shares fell ~19% in the month after the November 3 third-quarter report, when management said lower GLP-1 syringe volumes from one customer would hold 2027 growth to low single digits, William Blair downgraded the stock to Market Perform and UBS cut its target to $16.
More on Stevanato Group S.p.A. (STVN)
Whether STVN is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is STVN a buy or a sell?, and where the stock could go from here in the STVN stock forecast.
For income investors, whether STVN pays a dividend and how the payout looks is covered in does STVN pay a dividend? And to weigh STVN against a peer, read the full side-by-side comparisons: STVN vs RBC and STVN vs UBS.
Wondering how STVN fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Stevanato Group S.p.A.
Ask Walnut's AI anything about STVN and see how it fits what you own.
FAQ
What does Stevanato Group actually make?
+
Containers and devices for injectable medicines. That covers glass vials, prefillable syringes and cartridges under the Ompi brand, sterilized ready-to-use EZ-fill formats, and the Alina pen injector platform. A separate Engineering segment builds the assembly, filling and visual inspection machinery that drug makers run on their own production lines.
Is STVN a real US listing or an over-the-counter receipt?
+
Ordinary shares of Stevanato Group S.p.A. trade directly on the New York Stock Exchange under STVN, following the July 2021 initial public offering. No sponsored or unsponsored depositary receipt sits in between, and the company files with the SEC as a foreign private issuer, using Form 20-F annually and Form 6-K for quarterly results.
Why are Stevanato's results reported in euros?
+
The company is headquartered in Piombino Dese, Italy, and keeps its books in euros, so revenue, margins and earnings per share all arrive in EUR even though the shares are quoted in USD. Third-quarter 2026 revenue of ~EUR 326.1 million and adjusted diluted EPS of ~EUR 0.16 are euro figures. Putting a dollar sign on them overstates or understates the result depending on the exchange rate that day.
What are high-value solutions and why does the company keep mentioning them?
+
High-value solutions are the sterilized ready-to-use containers and integrated delivery systems that command better pricing than bulk glass. They reached ~46% of third-quarter 2026 revenue at ~EUR 149.4 million, though growth slowed to ~1% year over year as GLP-1 volumes fell, after ~16% growth in the second quarter. The rising share over recent years is what lifted adjusted EBITDA margin to ~27.2% in the third quarter, up ~150 basis points.
How much of Stevanato's revenue depends on GLP-1 drugs?
+
Management placed GLP-1 therapies at roughly ~17% to ~18% of total revenue in the third quarter of 2026, down from ~22% to ~23% on the second-quarter call, and said one customer's lower volumes tied to Nexa syringes will slow 2027 growth to low single digits. Non-GLP-1 biologics revenue rose more than ~30% in the quarter. Executives frame the wider injectable pipeline as the bigger prize, pointing to more than ~9,000 injectable assets in development with around ~60% of them biologics.
Why was free cash flow negative in the first half of 2026?
+
Construction. First-half capital expenditure ran ~EUR 119.6 million on new plants at Fishers in Indiana and Latina in Italy plus the Alina device program, which pushed free cash flow to ~negative EUR 26.6 million. The third quarter turned positive, with ~EUR 21.7 million of free cash flow on ~EUR 44.8 million of capital expenditure, and net debt eased to ~EUR 353.7 million at the end of September against ~EUR 114.9 million of cash. Full-year capital expenditure is guided to ~EUR 230 million to ~EUR 240 million gross, so the spending is still absorbing most of what operations produce this year.
Who controls Stevanato Group?
+
The founding Stevanato family, through the holding company Stevanato Holding S.r.l., which owns roughly four fifths of the shares. Italian loyalty-share provisions grant additional votes to long-held shares, so voting control sits further above the economic stake. Outside holders own a minority of a company whose strategic direction they cannot outvote, which is worth pricing in before comparing it with a widely held peer.
How does STVN compare with West Pharmaceutical Services?
+
Both sell into the same customers, but the products differ. West Pharmaceutical Services (NYSE: WST) leads in elastomer stoppers, seals and closures, whereas Stevanato leads in the glass container itself plus, increasingly, the assembled delivery device. Stevanato is a fraction of its size by market value (~$4.3 billion as of November 2026), reports in euros, and carries family control, so the two are related businesses with different risk profiles and are not interchangeable holdings.
How did Stevanato do in its latest quarter?
+
In the third quarter of 2026, reported November 3, revenue was ~EUR 326.1 million, up ~8% year over year, adjusted EBITDA rose ~14% to ~EUR 88.8 million (a ~27.2% margin) and adjusted EPS was ~EUR 0.16, in line with consensus on Yahoo's basis (0.18 vs 0.18). Full-year guidance was reaffirmed at ~EUR 1.26 to ~EUR 1.28 billion of revenue. The shares fell because management said lower GLP-1 volumes from one customer would hold 2027 growth to low single digits, and Engineering revenue dropped ~12%.
How has STVN stock performed in 2026?
+
As of the November 20, 2026 close at ~$15.70, STVN was down ~24% year to date and ~26% over one year, within a 52-week range of roughly ~$12.05 to ~$24.01. It fell ~19% over the prior month after the third-quarter report, a William Blair downgrade to Market Perform and a UBS target cut to $16 from $23. Walnut is not an investment adviser, and this is descriptive information, not a recommendation.
What do analysts expect from Stevanato next?
+
As of November 20, 2026, the 12 analysts Yahoo tracks had a mean price target of ~$19.46 and a Buy consensus. For the fourth quarter of 2026 they expect EPS of ~0.23 on ~EUR 366 million of revenue, and for full-year 2027 EPS of ~0.72 on ~EUR 1.3 billion of revenue, about ~6% revenue growth, which sits above the low-single-digit growth management described for 2027.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Stevanato Group S.p.A.'s investor relations page or your broker before making investment decisions.